Document is current
Any future updates will be listed below
-
Authors
Lentzas, Aristeidis
de Gooijer, Mark C.
Zuidema, Stefanie
Meurs, Amber
Çitirikkaya, Ceren H.
Venekamp, Nikkie
Beijnen, Jos H.
van Tellingen, Olaf
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 28 July 2024
First Online: 5 August 2024
Declarations
:
: The animal experiments were in accordance with 2010/63/EU and conducted under license AVD301002016595 and protocol 2.5.8776.
: Not Applicable.
: OT is co-inventor on a patent application (Bunt and Van Tellingen, 2014) dealing with development of an improved oral formulation for elacridar. All other authors declare no competing interests.
